Get the Stockscreener App
8.45
4.97%
0.40
After Hours:
8.40
-0.05
-0.59%
Adicet Bio Inc stock is traded at $8.45, with a volume of 116.37K.
It is up +4.97% in the last 24 hours and down -1.14% over the past month.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
See More
Previous Close:
$8.05
Open:
$8.07
24h Volume:
116.37K
Relative Volume:
0.64
Market Cap:
$81.12M
Revenue:
$24.99M
Net Income/Loss:
$-118.64M
P/E Ratio:
-6.4504
EPS:
-1.31
Net Cash Flow:
$-100.25M
1W Performance:
+0.36%
1M Performance:
-1.14%
6M Performance:
-18.64%
1Y Performance:
-46.22%
1-Day Range:
$8.07
$8.55
1-Week Range:
$7.94
$9.05
52-Week Range:
$7.1536
$17.44
Adicet Bio Inc Stock (ACET) Company Profile
Name
Adicet Bio Inc
Sector
Industry
Phone
617-482-2333
Address
131 DARTMOUTH STREET, BOSTON
Compare ACET with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACET
Adicet Bio Inc
|
8.45 | 77.28M | 24.99M | -118.64M | -100.25M | -1.31 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Adicet Bio Inc Stock (ACET) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-30-24 | Resumed | Guggenheim | Buy |
| Sep-11-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-27-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-27-23 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-01-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Mar-31-22 | Initiated | SMBC Nikko | Outperform |
| Mar-08-22 | Initiated | Truist | Buy |
| Mar-04-22 | Initiated | Jefferies | Buy |
| May-18-21 | Initiated | BTIG Research | Buy |
| Apr-23-21 | Initiated | H.C. Wainwright | Buy |
| Apr-14-21 | Initiated | Canaccord Genuity | Buy |
| Apr-08-21 | Initiated | Guggenheim | Buy |
| Nov-04-20 | Initiated | B. Riley Securities | Buy |
| Oct-27-20 | Initiated | JMP Securities | Mkt Outperform |
| Oct-16-20 | Initiated | Wedbush | Outperform |
View All
Adicet Bio Inc Stock (ACET) Latest News
Adicet Bio advances prula-cel autoimmune Phase 1 program - TipRanks
Biotech maps 2026 test plans for cell therapies in lupus and cancer - Stock Titan
Johnson & Johnson Touts Encouraging Results For Experimental Lupus Treatment - Benzinga
Canaccord Genuity lowers Adicet Bio stock price target to $18 from $128 - Investing.com Nigeria
Canaccord Genuity lowers Adicet Bio stock price target to $18 from $128 By Investing.com - Investing.com Nigeria
Adicet Bio (NASDAQ:ACET) Sees Unusually-High Trading VolumeStill a Buy? - MarketBeat
Adicet Bio (NASDAQ:ACET) Shares Up 4.5%What's Next? - MarketBeat
Adicet Bio implements reverse stock split to maintain listing - MSN
Adicet Bio, Inc. (NASDAQ:ACET) Short Interest Update - MarketBeat
Adicet Bio Implements Reverse Stock Split to Maintain Listing - TipRanks
Adicet Bio Announces Reverse Stock Split - marketscreener.com
Adicet Bio announces one-for-16 reverse stock split - MSN
Adicet Bio Stock Scheduled to Reverse Split on Tuesday, December 30th (NASDAQ:ACET) - MarketBeat
What's Going On With Adicet Bio Stock Today? - Benzinga
Adicet Bio To Implement 1-for-16 Reverse Stock Split On December 30 - Nasdaq
Adicet Bio to implement 1-for-16 reverse stock split By Investing.com - Investing.com Nigeria
Adicet Bio slides after announcing one-for-16 reverse stock split - TradingView — Track All Markets
Adicet Bio announces reverse stock split - marketscreener.com
Adicet Bio to implement 1-for-16 reverse stock split - Investing.com
Adicet Bio stock falls after announcing 1-for-16 reverse split - Investing.com Canada
Adicet Bio slides after announcing one-for-16 stock split - TradingView — Track All Markets
Adicet Bio Announces 1-for-16 Reverse Stock Split; Shares Fall Pre-Bell - marketscreener.com
Biotech shrinks share count 16 to 1—what changes for its shareholders - Stock Titan
Adicet Bio (NASDAQ:ACET) Shares Cross Below Two Hundred Day Moving AverageTime to Sell? - MarketBeat
CEO Moves: Can Adicet Bio Inc 1IJA stock hold up in economic slowdownJuly 2025 Market Mood & Reliable Volume Spike Alerts - moha.gov.vn
Brokerages Set Adicet Bio, Inc. (NASDAQ:ACET) Target Price at $7.33 - Defense World
Will Adicet Bio Inc. stock recover faster than peersEarnings Overview Summary & Growth Focused Entry Reports - Улправда
Can Adicet Bio Inc. stock sustain revenue growthWeekly Investment Recap & Reliable Volume Spike Trade Alerts - Улправда
Adicet Bio Shareholders Approve Flexible Reverse Stock Split - TipRanks
Why Adicet Bio Inc. stock remains a top recommendation2025 Trading Recap & Accurate Buy Signal Alerts - DonanımHaber
Is Adicet Bio Inc. stock a smart buy before Fed meetingWeekly Market Outlook & Free Safe Capital Growth Stock Tips - Улправда
How Adicet Bio Inc. stock reacts to Fed rate cuts2025 Market WrapUp & Risk Controlled Swing Alerts - Bölüm Sonu Canavarı
Market Wrap: Is Adicet Bio Inc. stock a smart buy before Fed meetingSwing Trade & Detailed Earnings Play Alerts - Улправда
Adicet Bio, Inc. (NASDAQ:ACET) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Adicet Bio reports progress in clinical trial enrollments - MSN
Nothing is Better Than Adicet Bio Inc (ACET) stock at the moment - setenews.com
Adicet Bio price target raised to $9 from $4 at H.C. Wainwright - MSN
Analysts Are Bullish on Top Healthcare Stocks: Adicet Bio (ACET), Palvella Therapeutics (PVLA) - The Globe and Mail
What dividend safety rating applies to Adicet Bio Inc. (1IJA) stockJuly 2025 Fed Impact & Technical Buy Zone Confirmations - Newser
Retail Trends: How Adicet Bio Inc stock trades during market volatilityBond Market & Low Drawdown Momentum Trade Ideas - moha.gov.vn
How higher bond yields impact Adicet Bio Inc. (1IJA) stockJuly 2025 Gainers & Growth Focused Entry Reports - Newser
Can Adicet Bio Inc. (1IJA) stock sustain breakout momentumTrade Risk Summary & Real-Time Chart Pattern Alerts - Newser
Is Adicet Bio Inc. (1IJA) stock bottoming after sell offJuly 2025 Rallies & Real-Time Market Trend Scan - Newser
Why Adicet Bio Inc. (1IJA) stock remains top ratedJuly 2025 Selloffs & Short-Term High Return Ideas - Newser
What analyst consensus implies for Adicet Bio Inc. (1IJA) stockJuly 2025 Breakouts & Fast Entry Momentum Alerts - Newser
Adicet Bio (ACET) Stock Analysis Report | Financials & Insights - Benzinga
Views of Wall Street’s Leading Experts on Adicet Bio Inc - setenews.com
Is Adicet Bio Inc. (1IJA) stock prepared for digital transitionTrade Volume Summary & Growth Focused Stock Reports - Newser
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Adicet Bio (Nasdaq: ACET) issues options for 20,600 shares at $0.65 exercise price - Stock Titan
Adicet Bio receives FDA fast track designation for its lupus erythematosus treatment - MSN
Adicet Bio Inc Stock (ACET) Financials Data
Revenue
Net Income
Cash Flow
EPS
28.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):